CytoDyn Inc. (CYDY) is “One to Watch”
PRO 140 is a leading monoclonal antibody/viral-entry inhibitor therapy under development for two different Human Immunodeficiency Virus (HIV) indications and is also being pursued for multiple opportunities in other immunologic indications such as autoimmune disease, chronic inflammation, certain cancers, and transplant rejection During 2017, 1.8 million people became newly infected with HIV, bringing the global total to 36.9 million people living with HIV (World Health Organization) Market potential for PRO 140 used as an anti-viral agent in combination with HAART is $1.2 billion; as a monotherapy maintenance/single-drug therapy the market is estimated at $3.8 billion CytoDyn Inc. (OTCQB: CYDY) is…